Absci Stock Buy or Sell? ABSI Stocks Forecast

Market Capitalization: 168 079 000 $
EBITDA: -99 703 000 $
Price to Earnings: None
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.539
Trailing PE: -
Forward PE: -
Shares Outstanding: 92395000

Absci Stock Buy or Sell? ABSI Stocks Analytic Forecasts

April 1, 2023 (06:09)

Absci Corporation (ABSI) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the ABSI stock market. Experts share their opinions on what to expect from the Absci Corporation stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Absci stocks.

Absci Corporation Stock Market Experts’ Analysis and Forecasting – Sell or Buy ABSI Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Edmund Ingham and is titled

“Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out”

is published on January 10 (2022) and has 4 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • Absci, a Vancouver-based drug discovery company that IPOd in July last year, has seen its market cap fall from >$2bn, to $665m at the time of writing.
  • This isn’t unusual for a drug discoverer/developer – Abcellera, also based in Vancouver, has seen its stock fall >80% while even Ginkgo Bioworks stock is -30% since IPO.
  • Absci has recently announced a partnership with Merck for up to three candidates which could be worth up to $640m, if all milestones are met.
  • That’s not necessarily likely but it does serve as validation of the young company’s technology and approach. Merck is revamping its R&D and Absci could make itself an indispensable part of that.
  • The deal will not do much for Merck in the short term, but it may help push Absci’s valuation higher – shares were 44%-plus on the news. Investing with a five-year investment horizon may offer a good ROI.

The author starts his analytic review with the following:

Investment Thesis – Market Has Depressed AI Drug Discovery Firms’ Valuations Absci (NASDAQ:ABSI) is a biotech focused on early stage drug development that IPO’d in July last year, raising ~$230m via the issuance of 12.5m shares at a price of $16.

The opinion of the author can be considered quite authoritative.
The number of 8482 followers confirms this.
Edmund Ingham is the contributor of experts community
since 2018 and has 449 works published.

One more noteworthy article is written by CEO Interviews under the title

“IPO Day With Absci CEO Sean McClain – The Google Of Synthetic Biology (Video)”

on July 22 (2021) and has 1 likes. The expert reflects trend of the market.

Нis theses make you think about whether to add ABSI stocks to your investment portfolio or not, and helps to work out your own Absci stock selling strategies:

  • Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today.
  • CEO Sean McClain discusses the emotion around going public, acquisitions in the time of Covid and being a technology driven company.
  • Providing tech solutions for pharma partners and what metric is key to watch over the next year.

CEO Interviews starts analysis with such words:

CEO Interviews has already 1790 followers, which shows, he is the one who cares for his words.
The contributor of experts community since 2021. Has published at least 204 articles.

Another analysis presented by Donovan Jones came out on July 20 (2021). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for ABSI stocks. It sounds like

“AbSci Proposes Terms For $200 Million IPO”

Article has got 2 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Absci Corporation, the expert says the following:

  • AbSci has filed to raise $200 million in a U.S. IPO.
  • The firm is commercializing a biologic development platform.
  • ABSI has promise but is still at a very early stage of commercialization and further development of its technologies and business model, so I’ll watch the IPO from the sidelines.

And here, what comes first:

Quick Take AbSci (NASDAQ:ABSI) has filed to raise $200 million in an IPO of its common stock, according to an S-1/A registration statement.

This author is very popular among the auditory. He has 18772 followers.

Donovan Jones is the contributor of experts community since 2016 and has at least 3790 analytic reviews published.

The Share Price of Absci Corporation (ABSI) for now

What analysts predict: $12
52-week high/low: $9.09 / $1.53

50/200 Day Moving Average: $2.393 / $2.992

The average stock price over the previous 50/200 days. For Absci stocks, the 50-day moving average is the resistance level for now. For ABSI stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for ABSI stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Bright Green Files For U.S. Direct Listing

Buy or Sell BGXX shares? Bright Green Files For U.S. Direct Listing
April 6, 2022
Bright Green Corporation has filed initial information for a direct listing on the Nasdaq Capital Market.

Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

Buy or Sell LLY shares? Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock
March 23, 2023
84% of shares held by 3370 “institutional” investors, with over 80% of its $315 Billion market capitalization traded in a year.

If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs

Buy or Sell JNJ shares? If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs
March 10, 2023
Recession is coming and with it plenty of scary headlines about crashing stock prices and financial doom.